Emerging Competition Issues Involving Follow-On Biologics

Darren Tucker joined V&E’s global antitrust practice as a partner in January 2018. Arriving from Morgan Lewis & Bockius LLP, he brings valuable insights to clients regarding competition enforcement and policy issues.

In this article Tucker examines the ways in which pharmaceutical firms have allegedly delayed product entry in violation of the antitrust laws and whether this conduct is likely to occur in the context of biologics and how the antitrust analysis of this conduct may differ for biologics.

Key Contacts

Partner

Darren Tucker

+1.202.639.6553

darrentucker@velaw.com

Related Insights

CLE Event

2020 Antitrust Developments in the Energy and Chemical Industries

Webcast

February 10, 2021
CLE Credit
The V&E Report

DOJ Antitrust Division Brings First Criminal No-Poach Case

January 13, 2021
Insight

2020 Energy and Chemicals Antitrust Report

V&E Antitrust Update

January 7, 2021
V&E⁺

Becoming a Partner in the Pandemic Era: V&E Attorneys Rise to the Challenge

December 16, 2020

This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice.